SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Market Closed 03-27 16:00:00 EDT

4.37

-0.58

-11.82%

盘后4.45

+0.08+1.95%

19:59 EDT

High4.84	Low4.32	Vol10.17M
Open4.84	D1 Closing4.95	Amplitude10.61%
Mkt Cap785.70M	Tradable Cap781.34M	Total Shares180.00M
T/O46.29M	T/O Rate5.68%	Tradable Shares179.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":4.365,"timestamp":1774641600000,"preClose":4.95,"halted":0,"volume":10173571,"hourTrading":{"tag":"盘后","latestPrice":4.45,"preClose":4.365,"latestTime":"19:59 EDT","volume":81318,"amount":361755.1419,"timestamp":1774655981542,"change":0.085,"changeRate":0.019473,"amplitude":0.030928},"delay":0,"changeRate":-0.11818181818181817,"floatShares":179000000,"shares":180000000,"eps":-0.246333,"marketStatus":"Market Closed","change":-0.585,"latestTime":"03-27 16:00:00 EDT","open":4.84,"high":4.84,"low":4.315,"amount":46285563.6602477,"amplitude":0.106061,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.246333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.95,"preHourTrading":{"tag":"盘前","latestPrice":4.859,"preClose":4.95,"latestTime":"09:29 EDT","volume":56479,"amount":278189.3816314,"timestamp":1774618191382,"change":-0.091,"changeRate":-0.018384,"amplitude":0.038384},"postHourTrading":{"tag":"盘后","latestPrice":4.45,"preClose":4.365,"latestTime":"19:59 EDT","volume":81318,"amount":361755.1419,"timestamp":1774655981542,"change":0.085,"changeRate":0.019473,"amplitude":0.030928},"volumeRatio":0.8591126283279705,"impliedVol":1.2839,"impliedVolPercentile":0.4542},"requestUrl":"/m/hq/s/SLS","defaultTab":"news","newsList":[{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4023","GETY","BYND","BK4139","CD","FLYX","NNE","BK4008","NFE","EVCM","ATLN","BK4606","BK4161","BK4604","PDYN","RXT","BK4603","NNEX","LCID","HURA","SLS","CRDF","BK4548","BK4116","BK4608","BK4138","BK4082","SERV","BK4144","BK4212","CV","BK4182"],"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","HURA","BK4608","FLYX","BK4144","BK4182","BK4548","SLS","BK4604","BK4212","BK4139","CRDF","GETY","BK4161","CV","NNEX","BK4138","BK4082","ATLN","BK4008","NNE","BK4606","BK4603","SERV","RXT","BK4116","CD","EVCM","PDYN","BK4077","NFE","LCID","BYND"],"gpt_icon":0},{"id":"2622000074","title":"Sims Group earnings: SLS now core to growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000074","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000074?lang=en_us&edition=fundamental","pubTime":"2026-03-26 06:19","pubTimestamp":1774477150,"startTime":"0","endTime":"0","summary":"The Sims Lifecycle Services  business is now a core driver of Sims Ltd  earnings growth, making up around 40% of group EBIT in the first half of FY26 and reflecting rapid growth as hyperscaler partners increase demand.SLS contributed approximately 40% of Sims Group's underlying EBIT in H1 FY26 . Group underlying EBIT rose to A$121.1 million in H1 FY26, up from A$73.0 million in H1 FY25. FY26 SLS underlying EBIT is forecast in the range of A$165–185 million. The newly introduced \"Memory GB Sold\" metric now gives a clearer picture of SLS's growth drivers, connecting volumes directly to revenue and reflecting the business's evolving role as a global leader in circular cloud solutions. SLS has also announced an expansion in Ireland, expected to be operational from July 2026, supporting future European growth.SLS is already a material earnings driver for Sims and is uniquely positioned at the intersection of structural growth trends in technology. Our capital-light business model and strong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/sims-group-earnings-sls-now-core-to-growth/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/sims-group-earnings-sls-now-core-to-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SLS"],"gpt_icon":0},{"id":"2621752839","title":"Sellas Life Sciences files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752839?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:05","pubTimestamp":1774040742,"startTime":"0","endTime":"0","summary":"17:02 EDT Sellas Life Sciences (SLS) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2621754499","title":"Sellas Life Sciences Group Inc: Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754499?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:02","pubTimestamp":1774040524,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2620738866","title":"Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738866?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:11","pubTimestamp":1774005095,"startTime":"0","endTime":"0","summary":"Alliance Global raised the firm’s price target on Sellas Life Sciences (SLS) to $10 from $7.50 and keeps a Buy rating on the shares after the compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-price-target-raised-to-10-from-7-50-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-price-target-raised-to-10-from-7-50-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620598279","title":"Sellas Life Sciences Group Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620598279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620598279?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:25","pubTimestamp":1773951948,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc reports results for the quarter ended December 31 - Earnings SummarySellas Life Sciences Group Inc SLS.OQ reported a quarterly adjusted loss of 5 cents per share for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N4072U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2620427983","title":"SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427983","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427983?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:17","pubTimestamp":1773951454,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51368249/sellas-life-sciences-gr-q4-eps-0-05-beats-0-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620002276","title":"SELLAS Life Sciences 2025 net loss narrows, cash position strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=2620002276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620002276?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:16","pubTimestamp":1773951411,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences 2025 net loss narrows, cash position strengthensOverviewUS biopharma firm's 2025 net loss narrowed from prior yearCompany advanced pivotal Phase 3 REGAL trial and expanded SLS009 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL1N4071FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620110276","title":"BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620110276","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620110276?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950746,"startTime":"0","endTime":"0","summary":"BRIEF-SELLAS Life Sciences FY Net Income USD -26.863 Million\n\n\nMar 19 (Reuters) - SELLAS Life Sciences FY basic EPS USD -0.25.\n\nFY operating income USD -28.274 million\nFY operating expenses USD 28.274 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX2945F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620276189","title":"Sellas Life Sciences FY Operating Income USD -28.274 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276189?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX2945F4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620527648","title":"Press Release: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620527648","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620527648?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950700,"startTime":"0","endTime":"0","summary":"-- Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  - Final Analysis upon Reaching 80 Events --. -- First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML --. -- $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises --. NEW YORK, March 19, 2026  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.European Collaboration to Advance SLS009 Clinical Program: In January 2026, SELLAS entered into a strategic collaboration with IMPACT-AML to expand SLS009 clinical program in Europe. Under the agreement, IMPACT-AML's STREAM clinical network will conduct a study of SLS009 in combination with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LU2463526074.USD","ASH","SLS","BK4139"],"gpt_icon":0},{"id":"2620276628","title":"Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276628","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276628?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:01","pubTimestamp":1773950516,"startTime":"0","endTime":"0","summary":"Sellas published its annual report  for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.General and administrative expense was USD 12.25 million.Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9tJqH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2620784322","title":"Sellas Life Sciences options imply 6.2% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620784322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620784322?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:35","pubTimestamp":1773941717,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 17:2. Implied volatility suggests the market is anticip...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-options-imply-6-2-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-options-imply-6-2-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2620299133","title":"Canaccord Genuity Reaffirms Their Buy Rating on Solstice Minerals Limited (SLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620299133?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:15","pubTimestamp":1773879312,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Paul Howard CFA maintained a Buy rating on Solstice Minerals Limited on March 17 and set a price target of A$1.85. Howard...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-solstice-minerals-limited-sls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-solstice-minerals-limited-sls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS"],"gpt_icon":0},{"id":"2620956512","title":"Sims Scores Upbeat Fiscal 2026 Guidance on Americas JV Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2620956512","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620956512?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:50","pubTimestamp":1773874211,"startTime":"0","endTime":"0","summary":"Sims  is treading strongly, with fiscal 2026 guidance well ahead of consensus, led by strength in the North and South America joint venture, offsetting a weak Specialty Steel  business, Jefferies said in a note on Wednesday.The metal recycling company's fiscal 2026 guidance was around 10% above Jefferies' estimates, supported by favorable US trading margins.Jefferies forecasts the North and South American joint venture to perform \"materially better\" in the second half of fiscal 2026 due to robust US ferrous and non-ferrous trading.However, a challenged set up for metals businesses remains, owing to oversupply in China steel. Scrap prices in both export markets and domestically also continue to be under pressure.The investment firm sees non-ferrous conditions, which were better-than-expected in the first half, to remain steady in the second half, it added. Jefferies maintained its underperformance rating due to lack of clarity on Specialty Steel and raised its price target to AU$19 from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGM.AU","BK7104","BK7129","BK4139","SLS.AU","SLS"],"gpt_icon":0},{"id":"2620040180","title":"Guess which ASX 200 stock is jumping 17% on strong FY26 guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040180","media":"MotleyFool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040180?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:15","pubTimestamp":1773789308,"startTime":"0","endTime":"0","summary":"Sims Ltd  shares are on the rise and catching the eye on Wednesday morning. In early trade, the ASX 200 stock is up 17% to $21.99. Image source: Getty Images Why is this ASX 200 stock rising today?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/guess-which-asx-200-stock-is-jumping-17-on-strong-fy26-guidance/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/guess-which-asx-200-stock-is-jumping-17-on-strong-fy26-guidance/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SAR.AU","BK7104","BK4135","SLS","BK7064","SAR","NAM.AU","SGM.AU","SLS.AU","BK7129","BK4139"],"gpt_icon":0},{"id":"2620929403","title":"Sellas Life Sciences to present preclinical SLS009 data at AACR conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620929403","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620929403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779749,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences (SLS) announced that preclinical data on SLS009, a potent, selective CDK9 inhibitor, will be presented in a poster session at ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-to-present-preclinical-sls009-data-at-aacr-conference-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-to-present-preclinical-sls009-data-at-aacr-conference-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2620825403","title":"SELLAS Life Sciences to present SLS009 AML preclinical data at AACR poster session","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825403","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779438,"startTime":"0","endTime":"0","summary":"Sellas said preclinical data on SLS009  will be presented at the AACR conference on April 17-22, 2026, at the San Diego Convention Center in San Diego, California. The company’s poster session is scheduled for April 21, 2026 at 2:00 PM in Poster Section 11 .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4XwcVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014021.USD","IE00BN0W2W23.USD","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014039.USD","BK4585","BK4588","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","SLS","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2619457800","title":"Sellas Life Sciences Group Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457800","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457800?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:14","pubTimestamp":1773659646,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc  expected to post a loss of6cents a share - Earnings Preview Sellas Life Sciences Group Inc SLS.OQ SLS.O is expected to  report results on March 18 (estimated) for the p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N4040TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":-0.083},{"period":"1month","weight":-0.0407},{"period":"3month","weight":0.5209},{"period":"6month","weight":1.6779},{"period":"1year","weight":2.7629},{"period":"ytd","weight":0.1578}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.030636},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01322},{"month":3,"riseRate":0.25,"avgChangeRate":-0.05858},{"month":4,"riseRate":0.454545,"avgChangeRate":0.091111},{"month":5,"riseRate":0.727273,"avgChangeRate":0.118591},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.198756},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.033023},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.058558},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.031827},{"month":10,"riseRate":0.363636,"avgChangeRate":0.051142},{"month":11,"riseRate":0.25,"avgChangeRate":-0.061889},{"month":12,"riseRate":0.25,"avgChangeRate":0.046982}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction